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Polypoidal choroidal vasculopathy
and photodynamic therapy with verteporfin
Abstract Background: We
evaluated, in a nonrandomised,
institutional, prospective study, the
efficacy of photodynamic therapy
(PDT) with verteporfin in age-related
macular degeneration (AMD) eyes
with polypoidal choroidal
vasculopathy (PCV) and subfoveal
exudation. Methods: A prospective
clinical and angiographic study was
done in 40 consecutive eyes with
PCV treated with PDT using masked
best-corrected visual acuity (VA) and
fluorescein and indocyanine green
angiographic features at baseline and
over 2 years. Results: Twenty-one
eyes completed 1-year follow-up and
showed, after a mean 2.9 PDT
sessions, VA improvement in 12 eyes,
no change in five eyes, and VA
decrease in four eyes. Leakage was
absent at the retinal and choroidal
level in 14 eyes at 1 year. Recurrence
occurred in one eye during the first
year. Six eyes completed 2 years of
follow-up and showed, after a mean
4 PDT sessions, VA improvement in
five eyes and VA decrease in one eye.
Leakage was absent at the retinal and
choroidal level in five eyes.
Recurrence occurred in four of these
six eyes during the second year of
follow-up. No serious adverse events
were observed during the 2 years of
follow-up. Conclusions: PDT with
verteporfin was shown to be safe and
effective for treating AMD eyes with
PCV with subfoveal involvement. VA
improvement and absence of leakage
were achieved, respectively, in 57.1%
and 66.6% of the eyes at 1 year.
Recurrences were more frequent
during the second year of follow-up.
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Introduction
Polypoidal choroidal vasculopathy (PCV) has been de-
scribed for the last two decades [8, 13]. In 1985, Stern and
colleagues [8] referred to it as “multiple recurrent sero-
sanguinous retinal pigment epithelial detachments in black
women.” In 1990, Yannuzzi et al. [13] further described
orange subretinal lesions as polypoidal dilations arising
from the choroidal vascular network and proposed the
name “idiopathic polypoidal choroidal vasculopathy.” In-
docyanine green angiography (ICG) was pointed out as
superior to fluorescein angiography (FA) for detecting and
characterizing these lesions [3, 7, 12]. Actually, atypical
cases of age-related macular degeneration (AMD), when
reexamined with ICG angiography, have been found to be
present in about 8–13% of white patients with clinical
appearance of exudative AMD [2, 12]. The natural course
of the disease is associated with chronic, multiple, re-
current serosanguinous detachments of the retinal pigment
epithelium (RPE) and neurosensory retina, and long-term
preservation of good vision is possible [10]. Photodynam-
ic therapy (PDT) using verteporfin has been shown to be
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effective and safe in patients with subfoveal PCV [1, 6].
However, definitive clinical trials to establish the efficacy
and safety of PDT in PCV are needed to confirm these
observations.
The purpose of this study was to evaluate, in a non-
randomised, institutional, prospective study, the efficacy
and safety of PDT with Visudyne (verteporfin) in neovas-
cular AMD eyes with PCV and subfoveal involvement.
Materials and methods
A prospective institutional study was performed in 40
consecutive eyes from 35 patients, 14 men and 21 women,
with AMD and PCV who were treated with PDT with
verteporfin between May 2000 and June 2004.
Inclusion criteria included the following: (1) symptom-
atic macular PCV with subfoveal exudation on FA, (2)
juxtafoveal, subfoveal, or extrafoveal active macular pol-
ypoidal lesions on ICG, (3) best-corrected initial visual
acuity (VA)≤20/40, (4) greatest linear dimension of active
lesion ≤5,400 μm, (5) signs of AMD in the study eye.
Exclusion criteria included the following: (1) previous
treatment for PCV (such as laser photocoagulation), (2)
other fundus diseases such as diabetic retinopathy, vascu-
litis, high myopia (≥6 diopters), vein or artery occlusion,
epiretinal membrane, angioid streaks, juxtafoveal telangi-
ectasias type 2, trauma, or intraocular infection or inflam-
mation, (3) any systemic contraindication to verteporfin or
angiographic dyes, (4) choroidal neovascularisation (CNV)
secondary to other causes such as high myopia, pseudohis-
toplasmosis, or idiopathic, (5) RPE tear or ripping, (6) ab-
sence of signs of AMD in the study eye and fellow eye.
The patients were observed at 3-month intervals. Clin-
ical observation, fundoscopy, fundus photography, FA,
ICG, and masked VA evaluation with Early Treatment Dia-
betic Retinopathy Study (ETDRS) charts were performed
at each visit.
PDT treatments or retreatments were applied in the pres-
ence of subfoveal juxta or extrafoveal active polypoidal
lesions on ICG and subfoveal exudation on FA (Figs. 1, 2).
Lesions were considered active in the presence of early and
late hyperfluorescence on ICG and subfoveal leakage on
FA. PDT treatments were performed within 3-month inter-
vals using the standard protocols of the Treatment of Age-
related Macular Degeneration with Photodynamic Therapy
(TAP) [9] and Verteporfin in Photodynamic Therapy (VIP)
[11] trials, with a few modifications. The same light dose of
50 J/cm2 and the same 3-month intervals between treat-
ments were used. However, we chose to treat the lesion with
the size visualised on ICG (largest diameter plus 1 mm).
Whenmore than one polypoidal vascular lesion was present
and separated by more than 1 mm, two treatments with
different spot sizes were used. Not all the haemorrhage area
Fig. 1 Case 15. Color picture (a) and ICG (b) at baseline. Subfoveal
polypoidal lesion on ICG and ring of lipid exudation on color picture.
At 1 year and after one PDT treatment, almost complete reabsorption
of lipid exudation is observed on color picture (c). FA shows late
staining, and on ICG there is a complete regression of polyps (d and
e). VA improved from 20/320 to 20/200.
974
was included in the area to be treated, unlike the standard
protocols in TAP [9] and VIP [11]. In the presence of
extensive haemorrhages, only 500 μm of the haemorrhage
adjacent to the PCV visualised on ICG was included in the
treatment spot. Retreatments were applied if ICG showed
any juxtafoveal, extrafoveal, or subfoveal vascular polyp-
oidal active lesion associated with subfoveal leakage on
FA.
We considered the recurrence of PCV to be present
when an active ICG lesion and subfoveal FA leakage re-
appeared following at least two consecutive visits (3-
month intervals) with no treatment (equaling a 9-month
interval).
All patients were older than 60 years of age at the time
of diagnosis and presented with signs of AMD, including
at least one intermediate drusen (between 63 and 125 μm)
and focal areas of hyper- and/or hypopigmentation, and/or
large drusens (≥125 μm). Only patients with 12 or more
months of follow-up were considered for the evaluation of
results.
The criteria for diagnosis of PCV are summarised in
Table 1. The diagnosis was positive only in the presence of
ICG features, and treatment was performed if an active
lesion was evident and subfoveal leakage was observed on
FA.
In all cases, stereo color and red-free fundus photo-
graphs and stereo fluorescein and digital ICG angiograms
were obtained with the Topcon ImageNet system. Images
were reviewed by two independent reviewers (R.S., J.R.F.
A.) at each 3-month interval and before any decision for
treatment/no treatment/retreatment. Any disagreement was
resolved by a third reviewer (J.G.C.V.).
VA was tested by a masked observer using the ETDRS
chart, and the best-corrected VA was obtained in all
patients. The evolution of VA was classified into three
groups: VA improvement (one or more lines), unchanged,
Fig. 2 Case 4. Subfoveal poly-
poidal lesion with lipid exuda-
tion at baseline: a color picture,
b early ICG, and c late ICG.
One year later and after two
PDT sessions, there was reab-
sorption of lipid exudation and
complete regression of poly-
poidal subfoveal lesions (d color
picture, e early ICG, f late ICG).
VA improved from 20/400 to
20/250.
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and VA loss (less than three lines, with severe meaning
loss of three or more lines).
The study was approved by an internal review com-
mittee and conducted in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki. Each
included patient signed an informed consent form after
being instructed on the experimental character of the PDT
treatment for PCV.
Results
Forty consecutive eyes of 35 patients, 21 women and 14
men, with an average age of 76.3±5 years (range 60–87)
were enrolled in the study. These eyes represented 10% of
all consecutive AMD eyes submitted to PDT between May
2000 and June 2004.
Eighteen patients aged 75.6±7.6 years, nine men and
nine women representing 21 eyes, completed 1 year of
follow-up. PCV lesions were subfoveal in 20 eyes and
juxtafoveal in one eye (case 8, Table 2). The mean number
of PDT sessions was 2.9±0.9. VA improved in 12 eyes
Table 1 Diagnosis criteria for PCV (RPE retinal pigment epithe-
lium, CNV choroidal neovascularisation)
Biomicroscopy and
stereo red-free
photography
FA ICG
Reddish-orange
lesions
Serosanguinous
detachment of
the RPE and
neurosensory
retina
Early and intermediate
phases: dilated network
of inner choroidal
vessels with terminal
hyperfluorescent
aneurysm-like
dilatations or “polyps”
Hypopigmentation
of RPE
CNV
Subretinal and
sub-RPE
haemorrhages
Hard exudates Late phases: two
patterns — (1) washout
(nonleaking lesions),
(2) hyperfluorescence
(active lesions)
Table 2 Evolution of VA, number of PDT sessions, presence or absence of ICG active lesions and FA leakage (exudation), and recurrences
at 12 and 24 months (SD standard deviation)
Initial
VA 20/
VA 12
months
20/
No treat
12 months
Lines 12
months
VA 24
months
Lines 24
months
No treat
24 months
Clinical/
angiographic status
12 months
Clinical/
angiographic status
at 24 months
Recurrences
1. AC 200 160 4 1 No exudation
2. AC 400 400 3 0 Exudation
3. AFS 100 100 4 0 Exudation
4. ADS 400 250 2 2 No exudation
5. CHC 50 40 4 1 40 1 6 Exudation No exudation Recurrence
6. CHC 40 25 4 2 50 −1 6 Exudation No exudation Recurrence
7. EJ 63 200 3 −5 No exudation
8. ES 50 50 2 0 40 1 2 No exudation No exudation Recurrence at
1 year
9. FPSD 400 200 4 3 Exudation
10. FPSD 80 640 3 −9 No exudation
11. JSM 160 160 2 0 No exudation
12. JNM 400 200 2 3 No exudation
13. JP 160 400 3 −4 No exudation
14. JPF 50 25 2 3 No exudation
15. MFN 320 200 1 2 200 2 1 No exudation No exudation
16. MGB 400 200 2 3 No exudation
17. MFB 100 160 4 −2 No exudation
18. MR 160 100 4 2 Exudation
19. MIVC 80 40 2 3 50 2 3 No exudation Exudation Recurrence
20. MJSF 100 50 4 3 63 2 6 Exudation No exudation Recurrence
21. MRF 160 160 2 0 No exudation
Mean 184 179 2.9 73 4
SD 138 150 0.9 62 2.2
Range 40–400 25–640 1–4 40–200 1–6
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(57.1%) and was unchanged in five eyes (23.8%). VA
decreased in four eyes (19%) by less than three lines in
one eye and by three lines in three eyes (Table 2). Mean
initial VA acuity of these 21 eyes was 20/200+2 (range
20/40 to 20/400), and mean final VA at 12 months was
20/200+3 (range 20/25 to 20/640).
Leakage was absent at the retinal and choroidal level in
14 eyes (66.6%) at 1 year. Recurrence occurred in one eye
during the first year (case 8, Table 2). The number of eyes
with VA less than 20/200 decreased from six at time of
enrollment to four at 1 year. The number of eyes with VA
≥20/50 increased from four to six during the same period.
Six eyes completed 2 years of follow-up and showed,
after 4±2.2 PDT sessions, VA improvement in five eyes
(less than three lines) and VA decrease in one eye (one
line). Mean initial VA acuity of these six eyes was 20/100+1
(range 20/40 to 20/320), and mean VA at 24 months was
20/63−2 (range 20/40 to 20/200). Recurrence occurred in
four of these eyes during the second year of follow-up
(Table 2). Leakage was absent at the retinal and choroidal
level in five of these six eyes at 2 years.
Severe subretinal and sub-RPE haemorrhage occurred
in one eye (case 13) more than 1 month after the PDT
session, causing significant VA loss and fibrosis. VA de-
crease occurred in three other eyes at 1 year (cases 7, 10,
17) and in another eye between the 18- and 24-month
visits (case 6). Subfoveal fibrosis was responsible for VA
decrease in cases 6 and 7, and subfoveal atrophy was
related to VA decrease in cases 10 and 17.
Baseline classification of the neovascular lesion of the
study eye, using only FA, showed occult choroidal neo-
vascularisation (OCNV) in all 21 eyes. ICG showed a di-
lated network of inner choroidal vessels with terminal
hyperfluorescent aneurysm-like dilatations and/or “polyps”
in all the cases.
No significant side effects were observed during the
study, including RPE ripping or tears, severe acute VA
loss, development of secondary CNV, photosensitivity,
low back pain, or catheter-induced complications.
Discussion
Our study evaluated the safety and efficacy of PDT with
Visudyne in AMD eyes with juxtafoveal or subfoveal PCV
on ICG and subfoveal exudation on FA. As far as we
know, only a prospective study was published until now
regarding PDT in PCV [1].
PCV is a relatively well-defined entity [2–4, 7, 8, 10,
12, 13]. In our study, all the eyes presented signs of AMD,
and the diagnosis of PCV was based on clinical and an-
giographic features (Table 1). In the presence of recurrent
serous-sanguineous subretinal and/or sub-RPE detach-
ments, the diagnosis is evident. When only FA is per-
formed, these exudative lesions are classified in most cases
as occult without classic CNV. ICG shows a typical pattern
of choroidal vessels with terminal hyperfluorescent aneu-
rysm-like dilations or “polyps” in the early and/or inter-
mediate phases. In late phases these lesions may become
hypofluorescent due to a washout effect (inactive lesions),
or they may remain hyperfluorescent-active lesions. All
the cases we submitted to PDT with Visudyne presented
juxtafoveal or subfoveal ICG-active lesions and exudation
on FA, with VA loss due to these lesions.
We found that PDT was effective and safe for treating
PCV in AMD eyes in a series of 21 eyes at 1 year of
follow-up. A total of 12 eyes (57.1%) showed some VA
improvement at 1 year, with six eyes (28.5%) gaining
three lines. The small group of six eyes with 2 years of
follow-up showed VA improvement in 83.3% of cases
(less than three lines) and VA loss in 16.6% of the eyes
(one line). The higher final VA at 2 years when compared
with the final VA at 12 months is not a result of pro-
gressive VA improvement. In fact, these six eyes presented
a higher initial VA, and three out of six had some VA
decrease between 12 and 24 months.
Recurrence of active lesions occurred in 4.7% of the
eyes during the first year of follow-up and in 66.6% during
the second year. The higher recurrence rate in eyes with
longer follow-up was not followed by significant VA loss.
In our series all patients were Caucasian. Females rep-
resented 50% of the patients with 1 year of follow-up and
60% of the 35 patients included in the study. This is in
accordance with other series with predominantly white or
black populations, in which 18–47% of the patients were
male [5, 12].
Our study has one important limitation: It had no con-
trol group. If we consider FA classification, almost all of
these eyes would have clinical indications for PDT (OCNV
with small lesions and/or VA 20/50). A control group would
not be ethically acceptable in these cases.
The natural course of the disease is becoming progres-
sively better understood. The disease has a remitting–
relapsing course and is associated clinically with chronic,
multiple, recurrent serosanguinous detachments of the
RPE and neurosensory retina. Long-term preservation of
good vision can be obtained. Approximately half the pa-
tients with PCV lesions in the posterior pole may have a
favourable course without treatment [10]. In the remaining
half, the disorder may persist for a long time with occa-
sional repeated bleeding and leakage, resulting in severe
macular damage and VA loss. Eyes with a cluster of grape-
like polypoidal dilations of the vessels may have a higher
risk for severe visual loss [10]. Most of the series an-
alysing the natural history of PCV describe lesions in the
posterior pole, differentiating macular from extramacular
and/or peripapillary polyps [1, 4, 5, 10, 12, 13]. Macular
involvement ranged from 25% [12] to 94% [10]. The
analysis of VA outcome must consider location of polyps.
Kwok et al. [4] followed the natural history of nine eyes
with macular involvement after a follow-up ranging from
5 to 60 months and found VA improvement of two lines in
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only one eye (11.1%), VA change of one line in one eye,
and VA decrease of two lines in seven eyes (77.7%).
Uyama et al. [10] followed 14 eyes with PCV (13 with
macular involvement) for a mean period of 39.9 months
and described VA improvement of two lines in five eyes
(35.7%) and VA decrease of two lines in four eyes
(28.5%). In our series we only treated eyes with macular
involvement and juxtafoveal or subfoveal lesions. Despite
this, PDT treatment with Visudyne has shown better re-
sults at 1 year than natural history. VA stabilisation or
improvement was achieved in 80.9% (gain of two lines in
47.6%), and VA loss of two lines was present in 19% of
the eyes.
Laser photocoagulation has been proposed for treating
PCV lesions [4, 5, 10]. VA decrease of two lines has been
shown to occur in 24–44% of the treated eyes with peri-
papillary and/or macular extrafoveal lesions [4, 5, 10].
Laser treatment of juxtafoveal or subfoveal lesions is not
feasible and will promote immediate VA loss. PDT with
Visudyne is an alternative.
As far as we know, only a prospective study was pub-
lished until now on PDT in PVC. Chan et al. [1] reported
that from a group of 22 PCV eyes from 21 Asian patients
(four extrafoveal, two juxtafoveal, and 16 subfoveal le-
sions) treated with a mean number of 1.6 PDT sessions, 21
(95%) had achieved a VA stabilisation or improvement at
1 year of follow-up. In 13 eyes (59%) there was a VA gain
of two lines, and in 50%of the cases had a final VA of 20/50.
Three of the four eyes with extrafoveal lesions showed an
improvement of three lines, with a final VA of 20/50. Our
results are not as impressive. However, there are some dif-
ferences between the series regarding potential impact on
VA prognosis. The presence of extrafoveal lesions is one of
them and is responsible for 27% of the cases with a final VA
of 20/50 and for 23% of the eyes with VA gain of two lines
in the series of Chan et al. [1]. Other differences are related
to race (all of our patients are Caucasian), AMD (all of them
had signs of AMD in both eyes), and older age (mean of
75.6 years in our series vs. mean of 66.6 years in Chan et
al.’s series [1]). How these factors contribute is yet to be
established.
We have treated only AMD patients with juxtafoveal or
subfoveal PCV active lesions. Only one eye presented a
juxtafoveal lesion, and its behaviour was apparently sim-
ilar to subfoveal lesions, with the exception of being the
only one with a recurrence in the first year of follow-up.
Most patients with evidence of PCV in one eye even-
tually develop similar lesions in the fellow eye [2]. We
found bilateral PCV in 14.3% of the patients. However,
31.4% of the 35 patients presented disciform scar in the
contralateral eye. The nature of the neovascular lesion
originating the disciform scar was impossible to establish
at that point. A PCVorigin could not be ruled out in these
cases.
The selection of the spot size for PDT may be a con-
troversial issue. The ICG hot spots would probably indi-
cate the size of the lesions to be treated. As other authors
have done [1], we chose to treat the lesion with the size
visualised on ICG (largest diameter plus 1 mm).
Leakage was absent at the retinal and choroidal level in
66.6% and 83.3% of the treated eyes at 12 and 24 months,
respectively (Table 3). The number of treatments neces-
sary to close the PCV lesion was widely variable (range of
one to six over 24 months). The mean number of treat-
ments was 1.9 and four at 12 and 24 months, respectively.
These numbers are lower than the number of PDT sessions
necessary to treat predominantly classic, OCNV, or mini-
mally classic lesions [9, 11]. However, they are higher
than those shown by Chan et al. [1].
One of the characteristics of PCV is the existence of
recurrent subretinal and sub-RPE serosanguinous detach-
ment. During follow-up, recurrence of exudation occurred
in one eye up to 12months and in four of the six eyes during
the second year of follow-up. The longer the follow-up, the
higher the probability of recurrence. More cases with longer
follow-up times are necessary to evaluate the recurrence
rate in PCV eyes treated with PDT. How PDT affects re-
currence rate is yet to be determined. VA decrease was not
related to recurrence rate.
In conclusion, PDTwith verteporfin is effective and safe
for treating active PCV lesions with subfoveal exudation.
VA improvement and absence of leakage at 1 year occurred,
respectively, in 57.1% and 66.6% of the eyes. The longer
the follow-up, the greater the probability of recurrence.
Table 3 VA change, absence of leakage, and number of treatments
at 12 and 24 months
Follow-
up (N=)
VA
improvement
VA no
change
VA
decrease %
Absence
of
leakage
No
treatments:
SD (range)
12
months
(N=21)
12 eyes
(57.1%)
5 eyes
23.8%
4 eyes 14 eyes
(66.6%)
2.9±0.9
(1–4)
<3 lines:
6 eyes
(28.5%)
1–2 lines:
1 eye
(4.7%)
=3 lines:
6 eyes
(28.5%)
=3 lines:
3 eyes
(14.2%)
24
months
(N=6)
5 eyes
(83.3%)
0 1 eye
(16.6%)
5 eyes
(83.3%)
4±2.2
(1–6)
<3 lines:
83.3%
<3 lines:
16.6%
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